Novartis Lawsuit

Sun Pharmaceutical Industries Ltd rose 2.30 per cent today to trade at Rs 625.75 after the company settled Novartis lawsuit over drugs.

The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

U.S. Attorney Preet Bharara in Manhattan said Novartis had since 2005 induced at least 20 pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic from competitors' drugs, in exchange for kickbacks disguised as rebates and discounts.

The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.

Swiss drugmaker Novartis told the Supreme Court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case that could change the rules for the country's healthcare sector.

Sun Pharmaceutical Industries Ltd rose 2.30 per cent today to trade at Rs 625.75 after the company settled Novartis lawsuit over drugs.

The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

U.S. Attorney Preet Bharara in Manhattan said Novartis had since 2005 induced at least 20 pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic from competitors' drugs, in exchange for kickbacks disguised as rebates and discounts.

The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.

Swiss drugmaker Novartis told the Supreme Court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case that could change the rules for the country's healthcare sector.